A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2021-01-07
Target enrollment:
Participant gender:
Summary
This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and
2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers. If
the dose-related safety, tolerability, and pharmacokinetics (PK) of ABI-H2158 in healthy
volunteers are deemed satisfactory, then the study will advance to Part 3, a Phase 1b,
dose-ranging assessment of ABI-H2158 in non-cirrhotic, CHB patients.